AdAlta – executive interview

Published on 29 March 2021

AdAlta is an Australian healthcare company focused on using its proprietary i-body discovery platform to target diseases, with an initial focus on conditions involving fibrosis. Its lead programme is AD-214 for the treatment of idiopathic pulmonary fibrosis, currently in Phase I. AdAlta has also licensed its platform to GE Healthcare for the purpose of diagnostic imaging.

In this interview, CEO Tim Oldham provides an overview of the company’s programmes and reviews the recently announced clinical data for AD-214 as well as the company’s partnership strategy.

Share this with friends and colleagues